Table 1.
Demographic and clinical characteristics by treatment cohort
| Cohort characteristics | High risk Sotrovimab N = 15,633 |
High risk No mAba, N = 1,514,868 |
P-value |
|---|---|---|---|
| Diagnosis month category,b no. (%) | |||
| 1 September 2021–30 November 2021 | 2143 (13.71) | 511,292 (33.75) | < 0.001 |
| 1 December 2021–28 February 2022 | 12,376 (79.17) | 820,817 (54.18) | |
| 1 March 2022–30 April 2022 | 1114 (7.13) | 182,759 (12.06) | |
| Regionc, no. (%) | |||
| 1 and 2 | 5450 (34.86) | 516,964 (34.13) | < 0.001 |
| 3 and 4 | 3336 (21.34) | 324,250 (21.40) | |
| 5 and 7 | 3277 (20.96) | 205,595 (13.57) | |
| 6 and 8 | 2055 (13.15) | 271,037 (17.89) | |
| 9 and 10 | 1506 (9.63) | 197,022 (13.01) | |
| Rurality, no. (%) | |||
| Rural | 2847 (18.21) | 208,637 (13.77) | < 0.001 |
| Urban | 12,786 (81.79) | 1,306,231 (86.23) | |
| Gender, no. (%) | |||
| Female | 9188 (58.77) | 855,221 (56.46) | < 0.001 |
| Male | 6445 (41.23) | 659,647 (43.54) | |
| Age, years, no. (%) | |||
| 0–17 | 87 (0.56) | 117,021 (7.72) | < 0.001 |
| 18–34 | 1909 (12.21) | 279,322 (18.44) | |
| 35–49 | 3815 (24.40) | 411,711 (27.18) | |
| 50–64 | 6627 (42.39) | 512,330 (33.82) | |
| 65–74 | 2348 (15.02) | 131,456 (8.68) | |
| 75 + | 847 (5.42) | 63,028 (4.16) | |
| Mean (SD) | 52.98 (14.53) | 45.90 (18.05) | < 0.001 |
| Median (IQR) | 55.00 (20) | 48.00 (25) | < 0.001 |
| Documented COVID-19 vaccine, no. (%) | |||
| Yes | 3177 (20.32) | 229,770 (15.17) | < 0.001 |
| No/unknown | 12,456 (79.68) | 1,285,098 (84.83) | |
| High-risk conditions (EUA) | |||
| Obesity (BMI ≥ 30 kg/m2) | 4335 (27.73) | 379,463 (25.05) | < 0.001 |
| Pregnant | 1203 (7.70) | 75,133 (4.96) | < 0.001 |
| CKD | 1571 (10.05) | 68,168 (4.50) | < 0.001 |
| Diabetes | 4081 (26.11) | 268,798 (17.74) | < 0.001 |
| Immunocompromising conditions/immunosuppressive therapy | 6525 (41.74) | 379,002 (25.02) | < 0.001 |
| COPD | 1105 (7.07) | 63,497 (4.19) | < 0.001 |
| Asthma | 709 (4.54) | 45,930 (3.03) | < 0.001 |
| Chronic lung disease | 2509 (16.05) | 193,149 (12.75) | < 0.001 |
| Sickle cell disease | 22 (0.14) | 3727 (0.25) | 0.007 |
| Congenital heart disease | 265 (1.70) | 23,741 (1.57) | 0.223 |
| Acquired heart disease | 5135 (32.85) | 323,485 (21.35) | < 0.001 |
| Cardiovascular disease | 4118 (26.34) | 227,764 (15.04) | < 0.001 |
| Hypertension | 8319 (53.21) | 627,283 (41.41) | < 0.001 |
| Neurodevelopmental disorder | 970 (6.20) | 188,172 (12.42) | < 0.001 |
| Medical device | 1462 (9.35) | 110,341 (7.28) | < 0.001 |
SD standard deviation, IQR interquartile range, EUA Emergency Use Authorization, BMI body mass index, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease
aIncludes 131 patients identified based on history of drug-induced anaphylaxis, which is not an EUA high-risk condition
bDiagnosis month category reflects the time period for when a circulating variant was or became predominant
cRegion: region 1 (CT, ME, MA, NH, RI, VT), region 2 (NJ, NY), region 3 (DE, DC, MD, PA, VA, WV), region 4 (AL, FL, GA, KY, MS, NC, SC, TN), region 5 (IL, IN, MI, MN, OH, WI), region 6 (AR, LA, NM, OK, TX), region 7 (IA, KS, MO, NE), region 8 (CO, MT, ND, SD, UT, WY), region 9 (AZ, CA, HI, NV), and region 10 (AK, ID, OR, WA)